FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer

Share:

Listens: 0

FDA Drug Information Updates

Science

FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer. Released July 25, 2017